# Efficacy and Safety of Alisporivir Triple Therapy in Chronic Hepatitis C Genotype 1 Treatment-naïve Participants

> **NCT01318694** · PHASE3 · COMPLETED · sponsor: **Debiopharm International SA** · enrollment: 1081 (actual)

## Conditions studied

- Hepatitis C

## Interventions

- **DRUG:** Alisporivir
- **DRUG:** Peginterferon alfa-2a
- **DRUG:** Ribavirin
- **DRUG:** ALV Placebo

## Key facts

- **NCT ID:** NCT01318694
- **Lead sponsor:** Debiopharm International SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03
- **Primary completion:** 2013-08
- **Final completion:** 2013-08
- **Target enrollment:** 1081 (ACTUAL)
- **Last updated:** 2016-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01318694

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01318694, "Efficacy and Safety of Alisporivir Triple Therapy in Chronic Hepatitis C Genotype 1 Treatment-naïve Participants". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01318694. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*